Tel-Aviv, Israel (March 5th, 2019) – VALFIX Medical announces a successful completion of its second round of investment. VALFIX medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.
"We have been very fortunate with our investors. The trust from our investors in our team and technology is invaluable and has been validated by their investment in our company more than once," Eli Bar, CEO and Founder of Valfix Medical, stated. “The completion of this round of capital raising enables us to strengthen the development team, continue to develop our technology, and strengthen our patent portfolio”
This investment, with an additional grant from the Israel Innovation Authority, completes the second investment round for the company.
About VALFIX Medical:
VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.
Devra Igra +972 73 374 4805 email@example.com
About Israel Innovation Authority:
The Israel Innovation Authority is an independent publicly funded agency, created to provide a variety of practical tools and funding platforms for early-stage entrepreneurs. https://innovationisrael.org.il/en/